Shenzhen Chipscreen Biosciences Company Description

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs.

The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a triple-pathway tumor-targeting inhibitor.

It is also developing CS23546, a small-molecule PD-L1 inhibitor; CS231295, a brain-penetrant Aurora B selective inhibitor; CS32582, a highly selective small-molecule allosteric inhibitor of tyrosine kinase 2; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192 a highly selective JAK3 kinase inhibitor.

The company was founded in 2001 and is headquartered in Shenzhen, China.

Shenzhen Chipscreen Biosciences Co., Ltd.

Country	China
Founded	2001
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	973
CEO	Xian-Ping Lu

Contact Details

Address: Zhigu Industrial Park Shenzhen, 518057 China
Phone	86 755 2695 2070
Website	chipscreen.com

Stock Details

Ticker Symbol	688321
Exchange	Shanghai Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100003LW0
SIC Code	2834

Key Executives

Name	Position
Dr. Xian-Ping Lu	Founder, Chairman, GM, Chief Executive Officer and President
Jian-Xun Li BA.CFA	Co-President, Head of Finance and Director
Dr. Desi Pan	Vice President, Deputy GM, Chief Scientific Officer and Head of the Early Research and Development Center
Ou Hai	Vice President, Deputy GM, Secretary of the Board, Head of Legal and Intellectual Property Department and Director
Dr. Zhi-Bin Li Ph.D.	Senior Vice President and Head of Product Development and Production
Liangji She	Senior Vice President and Head of the Commercial Segment
Dr. Leming Shi	Co-Founder
Dr. Weiming Hu	Co-Founder
Ji-Hui Yi MS	Vice President of Sales and Marketing